SCHEMBL9135019

SCHEMBL9135019

CC(C)(C)CCC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11760779 0.97 SPHK2 (0.39)
SCHEMBL12341240 0.83 SPHK2 (0.48)
SCHEMBL12341237 0.81 SPHK2 (0.52)
SCHEMBL28082072 0.78
SCHEMBL20198793 0.73
SCHEMBL179561 0.71
SCHEMBL17424318 0.71
SCHEMBL20198785 0.71
SCHEMBL5501237 0.71
SCHEMBL12619293 0.69 SIGMAR1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030912-B2 Cationic steroidal antimicrobial compounds with urethane linkages BRIGHAM YOUNG UNIVERSITY (US) 2024-07-09 US disclosed
US-20230372362-A1 METHODS FOR TREATING LUNG INFECTIONS AND INFLAMMATION BRIGHAM YOUNG UNIVERSITY (US) 2023-11-23 US disclosed
US-11739116-B2 Methods for treating inflammation, autoimmune disorders and pain BRIGHAM YOUNG UNIVERSITY (US) 2023-08-29 US disclosed
US-11690855-B2 Methods for treating lung infections and inflammation BRIGHAM YOUNG UNIVERSITY (US) 2023-07-04 US disclosed
US-20230050819-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-02-16 US disclosed
US-20210284629-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-09-16 US disclosed
US-20210238226-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-08-05 US disclosed
US-20210228723-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2021-07-29 US disclosed
US-10039285-B2 Ceragenin particulate materials and methods for making same BRIGHAM YOUNG UNIVERSITY (US) 2018-08-07 US disclosed
US-20180169114-A1 METHODS FOR REDUCING CELLULAR PROLIFERATION AND TREATING CERTAIN DISEASES BRIGHAM YOUNG UNIVERSITY (US) 2018-06-21 US disclosed
US-20130243842-A1 COMPOSITIONS AND METHODS FOR TREATING BONE DISEASES AND BROKEN BONES BRIGHAM YOUNG UNIVERSITY (US) 2013-09-19 US disclosed
US-20130236619-A1 ANTI-MICROBIAL FOOD PROCESSING COMPOSITIONS INCLUDING CERAGENIN COMPOUNDS AND METHODS OF USE BRIGHAM YOUNG UNIVERSITY (US) 2013-09-12 US disclosed
US-20130109656-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. 2013-05-02 US disclosed
US-8324257-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2012-12-04 US disclosed
US-8268871-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2012-09-18 US disclosed
US-20100331283-A1 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2010-12-30 US disclosed
US-7795282-B2 Mitotic kinesin inhibitors and methods of use thereof ARRAY BIOPHARMA INC. (US) 2010-09-14 US disclosed
US-20100041719-A1 MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2010-02-18 US disclosed
US-5472967-A Angiotensin II antagonists SYNTHELABO (FR) 1995-12-05 US disclosed
EP-0500409-A1 4-Pyrimidinone derivatives, their preparation and their application in therapy SYNTHELABO (FR) 1992-08-26 EP disclosed